Protocol Application
Use for new protocols and major amendments

	Part I. Protocol and	Contact Information	
A. Protocol Title:	raiti. Trotocorana	- Somuol Information	
Short Title (optional):			B. Protocol No.: E
C. Submission Type (choose one):	☐ New Protocol		dment a cover letter as well as revised ntegrating the changes.
D. Funding Source(s):			
E. Principal Investigator* Name and	Degree(s):		
Department:		School:	
Email:		Phone:	
F. ☐ *Check here if this study has co	-PIs, and include the o	ther PI on the Research Tea	m Form.
G. Administrative or Other Study Co	ontact Name and Degi	ree(s):	
Email:		Phone:	
	Part II. Type	of Research	
Section A:			
Does this protocol involve the use or	creation of a human e	embryo in vitro to derive hu	man embryonic stem (hES) cell
lines? No (skip to next section) Yes (complete the following	g)		
If Yes:			
Does the protocol involve		ines from pre-implantation er bryos you may need:	mbryos?
			mbryos, blastocysts, gametes, ainable or might become known to
	not limited to partheno		ntally creating a human embryo by uclear/chromosome transfer?

		Yes (complete the following	<i>g</i>)	
		If Yes:		
		a. List method(s) you	u will use to create the embryos:	
		b. Indicate the tissue	e(s) needed and the estimated number/amo	unt of each:
		provide the scientific ration nnot use existing lines.	ale for the need to derive new hES cell line	s. Include an explanation of why
Section B:				
		nvolve the use of hES or E itor cells ?	SCRO covered uses of human pluripoten	t stem (hPS) cells or human
		o to next section) mplete the following)		
If Y	es:			
5.	List a	ll lines you plan to use:		
		Line Identifier (It is okay to group/batch similar lines below.)	Type of Line	Source (From where will you obtain it?)*
			☐ hES ☐ hPS	
			Other. Describe:	
		*If hES cell line is not	already registered with ESCRO, also subm	it hESC Registration Form.
6.		this protocol involve <i>in vitr</i> No Yes	o use of hESC lines?	
7.		this protocol involve the us of for teratoma formation to No (continue to next quest Yes (complete the following	ion)	cells in non-human animals,
	If Y	es:	- /	
		but not limited to hES into any non-human for pluripotency does	colve the introduction of human pluripotent concells, those derived from human somatic contents and at any stage of prenatal development at any stage of prenatal development require ESCRO review. Insertion of humber blastocysts is prohibited.)	ells, amniotic fluid, or fetal tissue ent? (Teratoma formation to test
			olve research involving the insertion of hum I lls into the central nervous system of any	
8.	Does	this protocol involve resear	rch involving the introduction of human pluri	potent cells into humans?
		No Yes		

Part III. Research Summary

In addition to this form, and other approvals documentation, please submit the following for review:

- 1. Biosketches or CVs for all key personnel, and
- 2. A Research Summary, as described below:

2. Is this a banking protocol?

☐ No

☐ Yes

Research Summary: Please describe the research or educational aim(s)/objective(s) of the project and its significance. Provide its potential value and risks in obtaining or establishing significant information relevant to the understanding of humans or animals and/or improvement to human or animal health, or achievement of educational objectives.

¹ Under Massachusetts law, the creation of an embryo by the method of fertilization for purpose of research is prohibited, and criminal penalties may result. M.G.L. c 111L, Section 8(b).

² An embryo-like structure, as defined in the ISSCR Guidelines, is an experimentally generated structure that manifests human organismal form, integrated organ system development, and autonomous developmental capacity. Under MA law, and for Harvard ESCRO purposes, the term "embryo-like" is meant to capture entities that do not result from human fertilization and includes parthenotes, the products of nuclear transfer, "synthetic embryos", and other poorly-defined *in vitro* entities that, while demonstrating some features of embryonic patterning, are not embryos in a biologically functional sense.

- Clearly state the purpose and questions to be studied, and the key research procedures that will be used to answer these questions.
- Define all abbreviations and acronyms.
- . If there is more than one aim/objective, they should be stated in numbered sequence
- Please justify the estimated numbers for this study, including number of subjects to recruit, number of tissue samples (embryos, blastocysts, oocytes, skin biopsies, etc.) to be collected to derive stem cell lines, number of cells implanted (for research involving transplantation of human stem cells into non-human animals).
- For research involving transplantation of human stem cells or neural progenitor cells into non-human animals:
 - Indicate the age of the animal;
 - Detail the anatomical location of the injection site /introduction of human cells in the animal;
 - o Discuss how you will track the potential migration of transplanted human cells in the animal; and
 - Describe how you will prevent transplanted animals from breeding
 - Additionally, the ESCRO Committee is concerned with the human biology outcome of such transplantation protocols, for instance, inadvertently creating a chimera with enhanced cognitive function or altering the germline of an animal. Discuss the likelihood that the non-human animal might acquire cognitive functions thought to be distinctly human and, if anticipated, how you might assess and address this during the course of your research.

Part IV. Other Required Approvals and Documentation

Section A. Indicate approval or status for each of the following (if applicable):

	Type of review	Approved	OR	Pending	OR	Not applicable
1.	Institutional Review Board (IRB)					☐ no human subjects
2.	Institutional Animal Care and Use Committee (IACUC)					no vertebrate animal use
3.	Cost Allocation (If not required, please submit written documentation.)					
4.	Non-Harvard Review (list details below):					no collaborating institution
	a. Collaborating Institution Name: _					
	b. Collaborator's Protocol #:					
	c. Type of Review: ESCRO IRB Other, describe: (Choose as many as apply.)					
5.	Committee on Microbiological Safety (COMS)					

Part V. Principal Investigator's Certification

I have read and agree to abide by the policies of the H and any supplemental materials is accurate and comp lines derived.	arvard University ESCF lete. If this is a hESC lir	RO. I certify that the informate derivation protocol, I agr	ation in this form ee to register any
Principal Investigator's Signature	Date	 e	

Instructions for Protocol Application

Skip logic in Part II:

If the answer to a question allows the user to skip the rest of the questions in the section, the directions will say "skip to the next section." If the answer to a question allows the user to skip a sub-question within a section, but more questions in that section must be answered, the directions will say "continue to next question." The "next question" is the next question of the same level as the one just answered, e.g., if the answer to question 3 directs the user to continue to the next question, the user skips questions 3a and 3b but answers question 4.

For all tables, use the 'Tab' key to create more rows as needed.

IRB and IACUC protocols are not required to be appended to the ESCRO application. Presumably the research described in the ESCRO protocol reflects what is described in the other committee's protocol. For studies that are also considered human subjects research and require IRB approval, copies of the informed consent forms must be submitted to the ESCRO as well.

** Under Massachusetts law, No person shall knowingly create an embryo by the method of fertilization with the sole intent of donating the embryo for research.